This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Study Type
OBSERVATIONAL
Enrollment
500
Ferring Investigational Site
Omitama, Ibaraki, Japan
RECRUITINGAdverse Events
Frequency of Adverse Events
Time frame: From initiation of the administration, in case of embryo transfer is not performed, until 1 week after oocyte collection, and in case embryo transfer is performed, 6 weeks after embryo transfer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.